PCMC
TOVX icon

Planning Capital Management Corporation’s Theriva Biologics TOVX Stock Holding History

Planning Capital Management Corporation’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$6 Hold
4
– – ﹤0.01% 775
2024
Q2 		$26 Buy
+4
New +$35 ﹤0.01% 700

Other funds holding TOVX

HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Planning Capital Management Corporation's TOVX Position: Q3 2024 in Review

Planning Capital Management Corporation held its Theriva Biologics (TOVX) position steady in Q3 2024 at 4 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #775.

Planning Capital Management Corporation first reported a position in TOVX in Q2 2024 and has held it in 2 quarters since. The position peaked at $26 in Q2 2024. 18 funds tracked by Wall St. Rank hold TOVX as of Q3 2024.

  • Planning Capital Management Corporation held 4 shares of Theriva Biologics worth $6 as of Q3 2024.
  • Planning Capital Management Corporation left its Theriva Biologics share count unchanged in Q3 2024.
  • Theriva Biologics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #775 holding.
  • Planning Capital Management Corporation first reported a position in Theriva Biologics in Q2 2024 and has held it in 2 quarters since.
  • Planning Capital Management Corporation's Theriva Biologics position peaked at $26 in Q2 2024.
  • 18 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.